These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35837969)

  • 1. Implementation of a Hepatocellular Carcinoma Screening Program for At-risk Patients Safety-Net Hospital: A Model for National Dissemination.
    Lee RM; Darby R; Medin CR; Haser GC; Mason MC; Miller LS; Staley CA; Maithel SK; Russell MC
    Ann Surg; 2022 Sep; 276(3):545-553. PubMed ID: 35837969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Landscape of Hepatocellular Carcinoma : A US Safety Net Collaborative Analysis of Etiology of Cirrhosis.
    Lee RM; Gamboa AC; Turgeon MK; Yopp A; Ryon EL; Kronenfeld JP; Goel N; Wang A; Lee AY; Luu S; Hsu C; Silberfein E; Maithel SK; Russell MC
    Am Surg; 2020 Jul; 86(7):865-872. PubMed ID: 32721171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
    Tavakoli H; Robinson A; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
    Dig Dis Sci; 2017 Aug; 62(8):2174-2181. PubMed ID: 28474143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team.
    Duininck G; Lopez-Aguiar AG; Lee RM; Miller L; Dariushnia S; Wu C; Alese OB; Lin JY; Wedd J; Adams A; Maithel SK; Russell MC
    J Surg Oncol; 2019 Dec; 120(8):1365-1370. PubMed ID: 31642056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
    Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
    Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening.
    Robinson A; Tavakoli H; Cheung R; Liu B; Bhuket T; Wong RJ
    J Clin Gastroenterol; 2019 Jan; 53(1):65-70. PubMed ID: 29629906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.
    Mourad A; Deuffic-Burban S; Ganne-Carrié N; Renaut-Vantroys T; Rosa I; Bouvier AM; Launoy G; Cattan S; Louvet A; Dharancy S; Trinchet JC; Yazdanpanah Y; Mathurin P
    Hepatology; 2014 Apr; 59(4):1471-81. PubMed ID: 24677195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
    Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
    BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Aby E; Phan J; Truong E; Grotts J; Saab S
    J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
    Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
    Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for hepatocellular carcinoma in patients with advanced cirrhosis.
    Chalasani N; Horlander JC; Said A; Hoen H; Kopecky KK; Stockberger SM; Manam R; Kwo PY; Lumeng L
    Am J Gastroenterol; 1999 Oct; 94(10):2988-93. PubMed ID: 10520857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
    Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
    Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting.
    Wong CR; Garcia RT; Trinh HN; Lam KD; Ha NB; Nguyen HA; Nguyen KK; Levitt BS; Nguyen MH
    Dig Dis Sci; 2009 Dec; 54(12):2712-21. PubMed ID: 19876735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma.
    Jun TW; Yeh ML; Yang JD; Chen VL; Nguyen P; Giama NH; Huang CF; Hsing AW; Dai CY; Huang JF; Chuang WL; Roberts LR; Yu ML; Nguyen MH
    Liver Int; 2018 May; 38(5):895-902. PubMed ID: 29045023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.
    Innes H; Barclay ST; Hayes PC; Fraser A; Dillon JF; Stanley A; Bathgate A; McDonald SA; Goldberg D; Valerio H; Fox R; Kennedy N; Bramley P; Hutchinson SJ
    J Hepatol; 2018 Apr; 68(4):646-654. PubMed ID: 29155019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities to Improve Care of Hepatocellular Carcinoma in Vulnerable Patient Populations.
    Hoehn RS; Hanseman DJ; Dhar VK; Go DE; Edwards MJ; Shah SA
    J Am Coll Surg; 2017 Apr; 224(4):697-704. PubMed ID: 28069526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.